{
    "symbol": "CLSD",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-09 20:22:03",
    "content": " Last week, REGENXBIO reported that both the Wet AMD and diabetic retinopathy suprachoroidal clinical trials are on track to be completed in the first half of 2023 with additional interim trial data expected in the second half of 2023. With our XIPERE approval, our successful OASIS trial and the ongoing clinical development programs by our partners in the U.S. and China, suprachoroidal drug delivery via our SCS Microinjector is now more widely accepted than ever by retinal community. Last week, REGENXBIO reported that both the Wet AMD and diabetic retinopathy suprachoroidal clinical trials are on track to be completed in the first half of 2023 with additional interim trial data expected in the second half of 2023. With our XIPERE approval, our successful OASIS trial and the ongoing clinical development programs by our partners in the U.S. and China, suprachoroidal drug delivery via our SCS Microinjector is now more widely accepted than ever by retinal community."
}